Targeting Autophagy in Breast Cancer
Related Experiment Video
Updated: Dec 3, 2025

Author Spotlight: A Selective Luciferase-Based Assay for Monitoring ATG4B 27 Activity in Cells
Published on: June 30, 2023
Stefania Cocco1, Alessandra Leone2, Michela Piezzo1
1Breast Unit, Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale", Via Mariano Semmola 53, 80131 Napoli, Italy.
Abstract:
Breast cancer is a heterogeneous disease consisting of different biological subtypes, with differences in terms of incidence, response to diverse treatments, risk of disease progression, and sites of metastases. In the last years, several molecular targets have emerged and new drugs, targeting PI3K/Akt/mTOR and cyclinD/CDK/pRb pathways and tumor microenvironment have been integrated into clinical practice. However, it is clear now that breast cancer is able to develop resistance to these drugs and the identification of the underlying molecular mechanisms is paramount to drive further drug development. Autophagy is a highly conserved homeostatic process that can be activated in response to antineoplastic agents as a cytoprotective mechanism. Inhibition of autophagy could enhance tumor cell death by diverse anti-cancer therapies, representing an attractive approach to control mechanisms of drug resistance. In this manuscript, we present a review of autophagy focusing on its interplay with targeted drugs used for breast cancer treatment.
Insights
Breast cancer drug resistance can be overcome by targeting autophagy, a cellular process. Inhibiting autophagy may enhance cancer cell death when combined with targeted therapies.
Area of Science:
- Oncology
- Molecular Biology
- Cellular Biology
Background:
- Breast cancer is a complex disease with diverse subtypes, impacting treatment response and progression.
- Targeted therapies (e.g., PI3K/Akt/mTOR, cyclinD/CDK/pRb pathways) are used, but drug resistance is a significant challenge.
- Autophagy, a cellular degradation process, can be activated by cancer drugs as a survival mechanism.
Purpose of the Study:
- To review the role of autophagy in breast cancer.
- To explore the interplay between autophagy and targeted breast cancer therapies.
- To discuss autophagy inhibition as a strategy to overcome drug resistance.
Main Methods:
- Literature review of scientific articles on breast cancer, autophagy, and targeted therapies.
- Analysis of molecular mechanisms underlying autophagy activation and drug resistance.
- Synthesis of current research on targeting autophagy in breast cancer treatment.
Main Results:
- Autophagy can promote cancer cell survival, contributing to resistance against targeted drugs.
- Inhibiting autophagy in combination with targeted therapies shows potential for enhancing anti-tumor effects.
- Understanding autophagy modulation is crucial for developing effective breast cancer treatments.
Conclusions:
- Autophagy plays a dual role in breast cancer, but its inhibition is a promising strategy to combat drug resistance.
- Targeting autophagy offers a novel therapeutic avenue to improve outcomes for breast cancer patients.
- Further research is needed to optimize autophagy-targeted therapies for clinical application.
Related Concept Videos
Autophagy
An autophagic pathway consists of a series of signaling events activated in response to diverse stress and physiological conditions such as food deprivation,...
Delivery Pathways to the Lysosome
Endocytosis
In endocytosis, the cell membrane takes up macromolecules and particles from the surrounding medium. Clathrin-mediated...
Targeted Cancer Therapies
There are several types of targeted therapies against...
Autophagic Cell Death
Autophagy and Apoptosis
Autophagy can activate apoptosis. In normal conditions, the autophagy activating protein Beclin-1 and...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
The Intrinsic Apoptotic Pathway

